30 Day Trial

Anika Therapeutics' 4Q17 and 2017 Orthobiologic Revenue

Share:

Anika Therapeutics posted 4Q17 orthobiologic revenue of US $25.1MM, +3.1% vs. 4Q16, and 2017 revenue of $93.8MM, +4.6% vs. 2016.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.